日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

接受肾切除术治疗局部晚期透明细胞肾细胞癌患者的新辅助西特拉伐替尼联合纳武单抗治疗的 II 期临床试验

Jose A Karam #, Pavlos Msaouel #, Cara L Haymaker, Surena F Matin, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Ignacio I Wistuba, Enrica Marmonti, Dzifa Y Duose, Edwin R Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D Chin, Peter O

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

使用新型抗 CXCR4 IgG1 抗体 (PF-06747143) 靶向 CXCR4 通路治疗慢性淋巴细胞白血病

Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y Choi, Ale-Ali Amine, Laura Z Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R Fantin, Thomas J Kipps, Flavia Pernasetti, Januario E Castro

PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts

PF-00477736 介导检查点激酶 1 信号通路并增强多西他赛在异种移植中诱导的疗效

Cathy Zhang, Zhengming Yan, Cory L Painter, Qin Zhang, Enhong Chen, Maria E Arango, Kyle Kuszpit, Kenneth Zasadny, Max Hallin, Jill Hallin, Anthony Wong, Dana Buckman, Guizhen Sun, Ming Qiu, Kenna Anderes, James G Christensen